keyword
MENU ▼
Read by QxMD icon Read
search

anti-tnf

keyword
https://www.readbyqxmd.com/read/29452454/macular-edema-in-childhood-uveitis
#1
Justus G Garweg
BACKGROUND: Pediatric uveitis is associated with a high incidence of severe and frequently permanent visual loss. This article summarizes the current understanding of the disease and the therapeutic options that are available to improve treatment outcomes. METHODS: A Medline search spanning the last 10 years was undertaken using the key terms "pediatric uveitis" or "childhood uveitis" and "macular edema". Articles which appertained to case reports or small case series were excluded from consideration, whereas those in which the opinions of experts were expressed, as well as reviews, were not...
February 16, 2018: Klinische Monatsblätter Für Augenheilkunde
https://www.readbyqxmd.com/read/29452240/the-effect-of-non-anti-tnf-targeting-biologics-and-small-molecules-on-insulin-resistance-in-inflammatory-arthritis
#2
REVIEW
Francesco Ursini, Emilio Russo, Piero Ruscitti, Roberto Giacomelli, Giovambattista De Sarro
Inflammatory arthritides are chronic diseases characterised by an increase in cardiovascular risk, largely attributable to the synergy between high-grade systemic inflammation and an elevated prevalence of traditional cardiovascular risk factors. Amongst the latter, insulin resistance and type 2 diabetes (T2D) play a key position. Previous studies demonstrated a potential insulin-sensiting effect of anti-TNF biologic medications. For converse, less is known about the role of newer biologics or small molecules...
February 13, 2018: Autoimmunity Reviews
https://www.readbyqxmd.com/read/29448914/-express-quantitative-evaluation-to-efficacy-and-safety-of-therapies-for-psoriasis-a-network-meta-analysis
#3
Jingjing Lv, Dongmei Zhou, Yan Wang, Jingxia Zhao, Zhaoxia Chen, Jinchao Zhang, Tingting Di, Jing Hu, Bo Li, Ping Li
Therapies treating psoriasis can be categorized into 5 classes according to their mechanism: anti-metabolites (AM), anti-interleukin-12/23 agents (anti-IL 12/23), anti-interleukin-17 agents (anti-IL 17), anti-T-cell agent (ANT), and anti- tumor necrosis factor-α agent (anti-TNF-α). This network meta-analysis (NMA) aimed to give a quantitative and systemic evaluation of safety and efficacy for above five kinds of therapies. Odd ratios (ORs) and mean differences (MDs) were calculated to evaluate binary and continuous outcomes, respectively...
January 1, 2018: Molecular Pain
https://www.readbyqxmd.com/read/29448862/filgotinib-for-the-treatment-of-crohn-s-disease
#4
Remi Labetoulle, Stephane Paul, Xavier Roblin
Inflammatory Bowel Diseases, such as Crohn's disease (CD) and Ulcerative Colitis (UC), are widespread diseases (with an estimated 2.2 million Europeans affected), and even populations previously considered 'low risk' (such as Japan and India) are witnessing an increasing incidence. CD is a chronic, progressive immunologically driven disease, with an evolution characterized by succession of periods of progression and remission. New physiopathological pathways are continuously being discovered, the more we understand about how the disease appears and progresses, the more targets become available for the development of novel therapies...
February 15, 2018: Expert Opinion on Investigational Drugs
https://www.readbyqxmd.com/read/29446098/safety-efficacy-and-pharmacokinetics-of-vedolizumab-in-patients-with-simultaneous-exposure-to-an-anti-tumour-necrosis-factor
#5
S Ben-Horin, B Ungar, U Kopylov, A Lahat, M Yavzori, E Fudim, O Picard, Y Peled, R Eliakim, E Del Tedesco, S Paul, X Roblin
BACKGROUND: Data on combination-biologic treatment in (IBD) are still scant. AIM: To explore outcomes of patients co-exposed to anti-TNF and vedolizumab. METHODS: Patients starting vedolizumab having measurable anti-TNF levels after recently stopping adalimumab/infliximab ('VDZ-aTNF' group), were compared with control vedolizumab patients in a retrospective 1:2 matched case-control study. RESULTS: Seventy-five patients were included (25 VDZ-aTNF, 50 VDZ)...
February 15, 2018: Alimentary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/29445293/clinical-utility-of-ustekinumab-in-crohn-s-disease
#6
REVIEW
Paulo Gustavo Kotze, Christopher Ma, Abdulelah Almutairdi, Remo Panaccione
The introduction of anti-tumor necrosis factor (TNF) therapy marked an important milestone in the management of moderate-to-severe Crohn's disease (CD). However, there remains a pressing demand for alternative therapeutic options for patients with primary nonresponse, secondary loss of response, or intolerable side effects to conventional treatment and TNF antagonists. Ustekinumab (UST) is a fully human IgG1κ monoclonal antibody that inhibits the p40 subunit shared by the proinflammatory cytokines, the interleukin (IL)-12 and -23...
2018: Journal of Inflammation Research
https://www.readbyqxmd.com/read/29440950/relationship-between-etanercept-and-thyroid-function-in-patients-with-psoriasis-vulgaris
#7
Iulia Ioana Roman, Teodora Mocan, Meda-Sandra Orasan, Elena Mihaela Jianu, Carmen-Angela Sfrangeu, Remus-Ioan Orasan
Background and aim: Psoriasis vulgaris, a chronic inflammatory skin disease, requires a long term medication, in order to avoid relapsing episodes. TNF-alpha, one of the targeted molecule in psoriasis therapy, seems to be also involved in thyroid disorders etiopathogenesis. The aim of this study was to evaluate the relationship between anti TNF-alpha therapy and thyroid parameters: serum level of triiodothyronine (T3), free thyroxine (FT4), thyroid-stimulating hormone (TSH) and antithyroidperoxidase antibody (AbTPO) in psoriasis treated population...
2018: Clujul Medical (1957)
https://www.readbyqxmd.com/read/29439608/a-review-of-ustekinumab-in-the-treatment-of-psoriatic-arthritis
#8
Janet Roberts, Darren D O'Rielly, Proton Rahman
Psoriatic arthritis is an inflammatory arthritis associated with psoriasis. The IL-23/IL-17 axis is an important pathway in the development of psoriatic disease. Ustekinumab is a fully human monoclonal IgG1 antibody that binds to the p40 subunit of IL-12 and IL-23, which, in turn, inhibits downstream signaling pathways. PSUMMIT-1 and PSUMMIT-2 are two pivotal Phase III trials demonstrating global improvement in primary and secondary outcomes including inhibition of radiographic progression. Therapeutic benefit of ustekinumab for synovitis appears independent of previous disease modifying antirheumatic disease or anti-TNF exposure...
February 14, 2018: Immunotherapy
https://www.readbyqxmd.com/read/29436715/tnf-%C3%AE-level-affects-etanercept-clearance-tnf-%C3%AE-concentration-as-a-new-correction-factor-of-allometric-scaling-to-predict-individual-etanercept-clearances-in-patients-with-ankylosing-spondylitis
#9
Yuwei Deng, Li Hu, Wei Qiang, Zeneng Cheng, Lei Wang, Xiaoxia Wang
Etanercept (ETN) is a widely used anti- tumor necrosis factor-α (TNF-α) agent, which relieves the symptoms of ankylosing spondylitis (AS) by binding to TNF-α to inhibit its inflammation effects. In this study, the effect of TNF-α level on ETN clearance (CL) was investigated, and the TNF-α concentration was initially set as a correction factor for allometric scaling to improve the predictions of individual ETN CLs. Individual ETN CLs and TNF-α concentrations in healthy volunteers and patients with AS were determined by performing ETN pharmacokinetic studies in the two cohorts...
February 13, 2018: Clinical and Experimental Pharmacology & Physiology
https://www.readbyqxmd.com/read/29434844/oxaliplatin-and-infliximab-synergize-to-induce-regression-of-colon-cancer
#10
Di Huang, Jun Xue, Shuguang Li, Dongdong Yang
There is currently a lack of therapeutic options for patients with advanced colon cancer. Although certain chemotherapies are able to suppress the progression slightly, the response rate is low, and side effects of treatment and tumor recurrence continue to present problems for clinicians. Tumor necrosis factor-α (TNF-α) has been identified to possess tumor-promoting properties. In the present study, the effect of anti-TNF-α treatment (infliximab) in combination with chemotherapy on colon cancer was investigated...
February 2018: Oncology Letters
https://www.readbyqxmd.com/read/29432051/immunogenicity-and-persistence-of-a-prime-boost-re-vaccination-strategy-for-pneumococcal-vaccines-in-patients-with-rheumatoid-arthritis
#11
Mathilde Bahuaud, Constance Beaudouin-Bazire, Marine Husson, Anna Molto, Odile Launay, Frédéric Batteux, Maxime Dougados
OBJECTIVES: Patients with rheumatoid arthritis (RA) are at an increased risk of Pneumococcal infections. Immunogenicity and persistence of a prime-boost revaccination strategy using 13-valent/23-valent anti-pneumococcal vaccines was evaluated in patients with RA treated by Methotrexate (MTX) and anti-TNF. METHOD: Twenty-four patients with RA received one dose of PCV13 (Prevenar13ࣨ; Pfizer) followed two months later by one dose of PPV23 (Pneumovax®, Merck). Concentrations of IgG specific for 7 serotypes common to both vaccines and 3 uncommon serotypes, included only in the PPV23 were measured by ELISA and Opsonophagocytic Assay (OPA) at baseline and after 4, 12 and 24 months post-vaccine...
February 12, 2018: Human Vaccines & Immunotherapeutics
https://www.readbyqxmd.com/read/29431871/immunoassay-methods-used-in-clinical-studies-for-the-detection-of-anti-drug-antibodies-to-adalimumab-and-infliximab
#12
B Gorovits, D J Baltrukonis, I Bhattacharya, M A Birchler, D Finco, D Sikkema, M S Vincent, S Lula, L Marshall, T P Hickling
OBJECTIVE: To examine the assay formats used to detect anti-drug antibodies (ADA) in clinical studies of the anti-TNF monoclonal antibodies adalimumab and infliximab in chronic inflammatory disease and their potential impact on pharmacokinetic and clinical outcomes. METHODS: Using findings of a recent systematic literature review of the immunogenicity of 11 biologic/biosimilar agents, we conducted an ancillary qualitative review of a subset of randomized controlled trials and observational studies of the monoclonal antibodies against anti-tumor necrosis factor adalimumab and infliximab...
February 12, 2018: Clinical and Experimental Immunology
https://www.readbyqxmd.com/read/29431309/ankylosing-spondylitis-treatment-after-first-anti-tnf-drug-failure
#13
REVIEW
Maurizio Benucci, Arianna Damiani, Francesca Bandinelli, Valentina Grossi, Maria Infantino, Mariangela Manfredi, Francesca Li Gobbi, Piercarlo Sarzi-Puttini, Fabiola Atzeni
No abstract text is available yet for this article.
February 2018: Israel Medical Association Journal: IMAJ
https://www.readbyqxmd.com/read/29430672/review-article-predictors-of-response-to-vedolizumab-and-ustekinumab-in-inflammatory-bowel-disease
#14
REVIEW
A Barré, J-F Colombel, R Ungaro
BACKGROUND: Increased knowledge of pathways involved in the pathogenesis of IBD has led to the development of new treatment options for Crohn's disease (CD) and ulcerative colitis (UC). Two new biological agents have been recently approved for IBD: vedolizumab and ustekinumab. They have different therapeutic targets (α4 β7 integrin for vedolizumab and interleukin-12/23 pathways for ustekinumab) than the primary biological class, anti-tumour necrosis factor alpha (anti-TNF) agents. As the armamentarium for IBD increases in coming years, it will become important to understand factors associated with response in order to best position and personalise therapy...
February 12, 2018: Alimentary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/29430171/correlation-between-hla-haplotypes-and-the-development-of-antidrug-antibodies-in-a-cohort-of-patients-with-rheumatic-diseases
#15
Maurizio Benucci, Arianna Damiani, Francesca Li Gobbi, Francesca Bandinelli, Maria Infantino, Valentina Grossi, Mariangela Manfredi, Guillaume Noguier, Francesca Meacci
Introduction: The aim of this study was to investigate the correlation between human leukocyte antigen (HLA) haplotypes and the development of antidrug antibodies (ADAs) in a cohort of patients with rheumatic diseases. Patients and methods: We evaluated the presence of ADAs in 248 patients with inflammatory rheumatic diseases after 6 months of treatment with anti-TNF drugs: 26 patients were treated with infliximab (IFX; three with rheumatoid arthritis [RA], 13 with ankylosing spondylitis [AS], 10 with psoriatic arthritis [PsA]); 83 treated with adalimumab (ADA; 24 with RA, 36 with AS, 23 with PsA); 88 treated with etanercept (ETA; 35 with RA, 27 with AS, 26 with PsA); 32 treated with certolizumab (CERT; 25 with RA, two with AS, five with PsA); and 19 treated with golimumab (GOL; three with RA, seven with AS, nine with PsA)...
2018: Biologics: Targets & Therapy
https://www.readbyqxmd.com/read/29427369/pre-eclampsia-affects-procalcitonin-production-in-placental-tissue
#16
Chiara Agostinis, Damiano Rami, Paola Zacchi, Fleur Bossi, Tamara Stampalija, Alessandro Mangogna, Leonardo Amadio, Romana Vidergar, Liza Vecchi Brumatti, Giuseppe Ricci, Claudio Celeghini, Oriano Radillo, Ian Sargent, Roberta Bulla
PROBLEM: Procalcitonin (PCT) is the prohormone of calcitonin which is usually released from neuroendocrine cells of the thyroid gland (parafollicular) and the lungs (K cells). PCT is synthesized by almost all cell types and tissues, including monocytes and parenchymal tissue, upon LPS stimulation. To date, there is no evidence for PCT expression in the placenta both in physiological and pathological conditions. METHOD: Circulating and placental PCT levels were analysed in pre-eclamptic (PE) and control patients...
February 10, 2018: American Journal of Reproductive Immunology: AJRI
https://www.readbyqxmd.com/read/29422801/efficacy-of-restarting-anti-tumor-necrosis-factor-%C3%AE-agents-after-surgery-in-patients-with-crohn-s-disease
#17
Sakiko Hiraoka, Shiho Takashima, Yoshitaka Kondo, Toshihiro Inokuchi, Yuusaku Sugihara, Masahiro Takahara, Seiji Kawano, Keita Harada, Jun Kato, Hiroyuki Okada
Background/Aims: The efficacy of anti-tumor necrosis factor α (anti-TNFα) antibodies for postoperative Crohn's disease (CD) in patients who were treated with these agents prior to surgery is largely unknown. Methods: CD patients who underwent intestinal resection and received anti-TNFα agents after surgery were divided into 2 groups according to the presence or absence of preoperative anti-TNFα treatment: anti-TNFα restart group or anti-TNFα naïve group. Endoscopic recurrence after surgery was examined according to the preoperative conditions, including administration of anti-TNFα agents before surgery...
January 2018: Intestinal Research
https://www.readbyqxmd.com/read/29422799/comparison-of-time-until-elective-intestinal-resection-regarding-previous-anti-tumor-necrosis-factor-exposure-a-brazilian-study-on-patients-with-crohn-s-disease
#18
Paulo Gustavo Kotze, Daniela Oliveira Magro, Barbara Saab, Mansur Paulo Saab, Lilian Vital Pinheiro, Marcia Olandoski, Maria de Lourdes Setsuko Ayrizono, Carlos Augusto Real Martinez, Claudio Saddy Rodrigues Coy
Background/Aims: The use of anti-tumor necrosis factor (anti-TNF) agents seems to reduce surgical rates and delay surgical procedures in prospective trials and population-based studies in the management of Crohn's disease (CD). This study aimed to identify whether preoperative anti-TNF agents influence the time from diagnosis to surgery. Methods: An observational retrospective cohort study was conducted on patients with CD submitted to intestinal resections due to complications or medical therapy failure in a period of 7 years...
January 2018: Intestinal Research
https://www.readbyqxmd.com/read/29422794/asian-organization-for-crohn-s-and-colitis-and-asia-pacific-association-of-gastroenterology-consensus-on-tuberculosis-infection-in-patients-with-inflammatory-bowel-disease-receiving-anti-tumor-necrosis-factor-treatment-part-2-management
#19
REVIEW
Dong Il Park, Tadakazu Hisamatsu, Minhu Chen, Siew Chien Ng, Choon Jin Ooi, Shu Chen Wei, Rupa Banerjee, Ida Normiha Hilmi, Yoon Tae Jeen, Dong Soo Han, Hyo Jong Kim, Zhihua Ran, Kaichun Wu, Jiaming Qian, Pin-Jin Hu, Katsuyoshi Matsuoka, Akira Andoh, Yasuo Suzuki, Kentaro Sugano, Mamoru Watanabe, Toshifumi Hibi, Amarender S Puri, Suk-Kyun Yang
Because anti-tumor necrosis factor (anti-TNF) therapy has become increasingly popular in many Asian countries, the risk of developing active tuberculosis (TB) among anti-TNF users may raise serious health problems in this region. Thus, the Asian Organization for Crohn's and Colitis and the Asia Pacific Association of Gastroenterology have developed a set of consensus statements about risk assessment, detection and prevention of latent TB infection, and management of active TB infection in patients with inflammatory bowel disease (IBD) receiving anti-TNF treatment...
January 2018: Intestinal Research
https://www.readbyqxmd.com/read/29422793/asian-organization-for-crohn-s-and-colitis-and-asia-pacific-association-of-gastroenterology-consensus-on-tuberculosis-infection-in-patients-with-inflammatory-bowel-disease-receiving-anti-tumor-necrosis-factor-treatment-part-1-risk-assessment
#20
REVIEW
Dong Il Park, Tadakazu Hisamatsu, Minhu Chen, Siew Chien Ng, Choon Jin Ooi, Shu Chen Wei, Rupa Banerjee, Ida Normiha Hilmi, Yoon Tae Jeen, Dong Soo Han, Hyo Jong Kim, Zhihua Ran, Kaichun Wu, Jiaming Qian, Pin-Jin Hu, Katsuyoshi Matsuoka, Akira Andoh, Yasuo Suzuki, Kentaro Sugano, Mamoru Watanabe, Toshifumi Hibi, Amarender S Puri, Suk-Kyun Yang
Because anti-tumor necrosis factor (anti-TNF) therapy has become increasingly popular in many Asian countries, the risk of developing active tuberculosis (TB) among anti-TNF users may raise serious health problems in this region. Thus, the Asian Organization for Crohn's and Colitis and the Asia Pacific Association of Gastroenterology have developed a set of consensus statements about risk assessment, detection and prevention of latent TB infection, and management of active TB infection in patients with inflammatory bowel disease (IBD) receiving anti-TNF treatment...
January 2018: Intestinal Research
keyword
keyword
34737
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"